Regenicin Inc (RGIN)

[stk_maniac]

From 10Q
Overview
The company’s major objective for 2018 remains to secure the required funding to finalize some additional requirements of the IND application, and begin the clinical trials. It is estimated that the cost to finalize the IND will be approximately 1.5 million dollars, and the cost to complete Phase 1 of the clinical trial will be approximately 2 million dollars. As previously reported, our goal in obtaining this funding has been to minimize shareholders' dilution as much as possible. Consequently, we are primarily pursuing financing through the issuance of a debt instrument and international licensing agreements. We have been working on a significant debt financing over the last 6 months and hope to complete this form of financing during the coming quarter. In addition, earlier this month, our CEO, Randall McCoy began discussions with Saudi Arabian ministers related to potential joint venture opportunities.